HCPCS
J0485
1 mg = 1 unit
Phase 1
Identify what you're billing
Confirm EBV status, the right dosing phase, and that the indication is adult kidney transplant.
About Nulojix FDA label verified May 2026
Nulojix (belatacept) is a soluble fusion protein consisting of the modified extracellular domain of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to the modified Fc portion of human IgG1. Belatacept binds CD80 and CD86 on antigen-presenting cells, blocking the CD28-mediated costimulatory signal required for T-cell activation — the same molecular family as abatacept (Orencia, J0129) but engineered for higher binding avidity to support solid-organ transplant immunosuppression.
Marketed by Bristol Myers Squibb, Nulojix was approved by the FDA on June 15, 2011 for the prophylaxis of organ rejection in adult kidney transplant recipients, in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. It is used as a calcineurin-inhibitor-sparing maintenance regimen and is administered as a monthly IV infusion in the maintenance phase — a distinct adherence and access profile compared with daily oral tacrolimus or cyclosporine.
Use is restricted to EBV-seropositive recipients only through a contraindication and the FDA-approved boxed warning (there is no separate REMS program). The single boxed warning — "POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS" — covers: PTLD risk (predominantly CNS, substantially higher in EBV-seronegative recipients); the requirement that Nulojix only be prescribed by physicians experienced in immunosuppressive therapy and kidney transplant management; general immunosuppression-related infection and malignancy risk; and the recommendation against use in liver transplant (increased graft loss and death). Progressive multifocal leukoencephalopathy (PML) and other serious CNS infections are addressed in Warnings & Precautions, not separately boxed. Pivotal evidence comes from the BENEFIT and BENEFIT-EXT randomized trials and their long-term extension publications (NEJM 2010, 2016).
Nulojix vs. Orencia — same molecular family, different drug FDA verified May 2026
Belatacept (J0485) and abatacept (J0129) are sister CTLA-4-Ig molecules from BMS. They are NOT interchangeable.
Belatacept was engineered from abatacept by two amino-acid substitutions (L104E, A29Y) that increase binding avidity to CD80/CD86 by roughly 2–4× — a deliberate change to provide sufficient T-cell costimulation blockade for solid-organ transplant. The two products have separate FDA labels, separate safety profiles (Nulojix carries a boxed warning, Orencia does not), separate HCPCS codes, separate dosing regimens, and entirely separate indication sets. They are not biosimilars and are not therapeutic alternatives for each other.
| Nulojix (belatacept) | Orencia (abatacept) | |
|---|---|---|
| HCPCS | J0485 (1 mg = 1 unit) | J0129 (10 mg = 1 unit) |
| Generic | belatacept | abatacept |
| Manufacturer | Bristol Myers Squibb | Bristol Myers Squibb |
| Indication | Adult kidney transplant rejection prophylaxis | RA, polyarticular JIA, PsA, aGVHD prevention |
| EBV requirement | EBV-seropositive only (boxed warning + contraindication) | None — no EBV restriction |
| Dose | 10 mg/kg initial → 5 mg/kg maintenance q4w | Weight-tiered 500/750/1,000 mg fixed q4w (adult RA) |
| Vial | 250 mg single-dose lyophilized | 250 mg single-dose lyophilized |
| Route | IV infusion 30 min | IV infusion 30 min (also SC ClickJect, not under J0129) |
| Admin CPT | 96365 (+ 96366 if >1 hr) — non-chemo IV | 96365 (+ 96366 if >1 hr) — non-chemo IV |
| Boxed warning | Yes — PTLD / infection / malignancy from immunosuppression; not for liver transplant | None |
| Pediatric use | No — not established | Yes — JIA ≥6 yr (IV) / ≥2 yr (SC) |
Common claim error: billing J0129 for belatacept or J0485 for abatacept. The two J-codes
also have different unit conventions (J0485 = 1 mg per unit, J0129 = 10 mg per unit), so unit miscalculation
compounds the descriptor mismatch — a 700 mg belatacept dose is 700 units of J0485 but would be coded
as 70 units if mistakenly billed under J0129. Verify the active ingredient on the label and the indication
before submitting the claim.
Dosing & unit math FDA label verified May 2026
Two distinct dosing phases. Initial = 10 mg/kg × 6 doses through week 12. Maintenance = 5 mg/kg q4w from week 16 onward.
Initial phase — 10 mg/kg IV
The initial phase begins on the day of transplant and continues through week 12 post-transplant. Doses are calculated at 10 mg/kg of recipient body weight, rounded to the nearest 12.5 mg increment per FDA label. Six initial-phase doses are administered total.
| Dose # | Timing | Dose | Notes |
|---|---|---|---|
| 1 | Day 1 | 10 mg/kg | Day of transplant, prior to implantation |
| 2 | Day 5 | 10 mg/kg | Within 24 hr after transplant (±1 day) |
| 3 | End of week 2 | 10 mg/kg | ±3 days |
| 4 | End of week 4 | 10 mg/kg | ±3 days |
| 5 | End of week 8 | 10 mg/kg | ±3 days |
| 6 | End of week 12 | 10 mg/kg | ±3 days — last initial-phase dose |
Maintenance phase — 5 mg/kg IV q4w
- First maintenance dose: end of week 16 post-transplant
- Then every 4 weeks (±3 days) thereafter, indefinitely
- ~13 maintenance doses per year (q4wk × 52 weeks)
- Used with concomitant mycophenolate mofetil and corticosteroid taper per BENEFIT regimen
Concomitant immunosuppression
Nulojix is used as part of a multidrug immunosuppression regimen, never as monotherapy. The BENEFIT pivotal trials used the following regimen, which payers expect to see documented on the PA:
- Induction: basiliximab (or per institutional protocol)
- Antimetabolite: mycophenolate mofetil (MMF)
- Corticosteroids: taper per institutional protocol
- Infection prophylaxis: CMV, PJP, and (per institutional protocol) HSV prophylaxis
Worked example — 70 kg adult kidney transplant recipient, initial-phase dose
# Step 1: calculate the dose (initial phase)
Weight: 70 kg × 10 mg/kg = 700 mg (already a 12.5 mg multiple — no rounding needed)
# Step 2: vials needed (250 mg single-dose vials)
700 mg ÷ 250 mg/vial = 2.8 vials → round up to 3 vials (750 mg drawn)
Waste: 750 mg − 700 mg = 50 mg discarded
# Step 3: billing lines
Line 1 — administered: J0485 700 units JZ
Line 2 — waste: J0485 50 units JW
Admin: 96365 (30-min therapeutic IV, non-chemo)
# Step 4: reimbursement (Q2 2026 ASP+6% = $3.893/mg)
Drug payment (administered): 700 × $3.893 = $2,725.10
Wasted drug (JW): 50 × $3.893 = $194.65
Total drug per initial dose: $2,919.75 before sequestration
Weight: 70 kg × 10 mg/kg = 700 mg (already a 12.5 mg multiple — no rounding needed)
# Step 2: vials needed (250 mg single-dose vials)
700 mg ÷ 250 mg/vial = 2.8 vials → round up to 3 vials (750 mg drawn)
Waste: 750 mg − 700 mg = 50 mg discarded
# Step 3: billing lines
Line 1 — administered: J0485 700 units JZ
Line 2 — waste: J0485 50 units JW
Admin: 96365 (30-min therapeutic IV, non-chemo)
# Step 4: reimbursement (Q2 2026 ASP+6% = $3.893/mg)
Drug payment (administered): 700 × $3.893 = $2,725.10
Wasted drug (JW): 50 × $3.893 = $194.65
Total drug per initial dose: $2,919.75 before sequestration
Worked example — same 70 kg recipient, maintenance-phase dose
# Maintenance phase: 5 mg/kg
70 kg × 5 mg/kg = 350 mg (12.5 mg multiple — no rounding)
# Vials: 350 mg ÷ 250 mg = 1.4 → 2 vials drawn
Waste: 500 mg − 350 mg = 150 mg discarded
# Billing lines
Line 1 — administered: J0485 350 units JZ
Line 2 — waste: J0485 150 units JW
# Reimbursement (Q2 2026)
Administered: 350 × $3.893 = $1,362.55
Wasted (JW): 150 × $3.893 = $583.95
Total per maintenance dose: $1,946.50 before sequestration
70 kg × 5 mg/kg = 350 mg (12.5 mg multiple — no rounding)
# Vials: 350 mg ÷ 250 mg = 1.4 → 2 vials drawn
Waste: 500 mg − 350 mg = 150 mg discarded
# Billing lines
Line 1 — administered: J0485 350 units JZ
Line 2 — waste: J0485 150 units JW
# Reimbursement (Q2 2026)
Administered: 350 × $3.893 = $1,362.55
Wasted (JW): 150 × $3.893 = $583.95
Total per maintenance dose: $1,946.50 before sequestration
Reconstitution (silicone-free syringe required)
Each 250 mg vial is reconstituted with 10.5 mL sterile water for injection using the manufacturer-supplied silicone-free disposable syringe — silicone in standard syringes can produce translucent particulate that requires the dose to be discarded. Resulting concentration is 25 mg/mL. Calculated dose volume is then added to a 0.9% NaCl or D5W infusion bag (final concentration 2–10 mg/mL). Infuse over 30 minutes through a 0.2–1.2 micron low-protein-binding inline filter. Use within 24 hr if refrigerated; complete infusion within 24 hr of reconstitution.
NDC reference FDA NDC Directory verified May 2026
| NDC (10 / 11-digit) | Strength | Package Size | Units/Vial (J0485) |
|---|---|---|---|
0003-0371-13 / 00003-0371-13 |
250 mg | Single-dose lyophilized vial — 1 vial per carton | 250 units (1 mg = 1 unit) |
Use the carton-level NDC on the claim form. Payers expect carton NDC on the CMS-1500
Box 24A shaded area with the
N4 qualifier. The Nulojix carton NDC is 00003-0371-13.
Bill multiples based on vials drawn (e.g., 3 cartons for the 700 mg / 70 kg initial-phase dose).
UoM and quantity: After reconstitution, belatacept is reported in mL based on the
reconstituted 25 mg/mL concentration. A 700 mg dose drawn from 3 vials = 30 mL drawn (3 × 10 mL).
Use
ML as the unit-of-measure qualifier on the NDC line.
Phase 2
Code the claim
96365 (NOT 96413). Document EBV status. Split initial vs maintenance phase clearly.
Administration codes CPT verified May 2026
Belatacept is a non-cytotoxic biologic. Therapeutic IV codes apply — not chemotherapy administration.
| Code | Description | When to use |
|---|---|---|
96365 |
Intravenous infusion, for therapy / prophylaxis / diagnosis (other than chemo); up to 1 hour | Primary code for Nulojix. The 30-minute standard infusion fits cleanly within the 1-hour window. |
96366 |
Each additional hour beyond 96365 (list separately in addition to primary) | Add when infusion plus required observation extends past 1 hour. Most Nulojix infusions stay within 96365 alone. |
96413 / 96415 |
Chemotherapy administration, IV infusion | NOT appropriate. Belatacept is a non-cytotoxic CTLA-4-Ig fusion protein and does not meet AMA chemo admin criteria. Will trigger denials and audit risk. |
96367 |
Each additional sequential infusion (different drug) | Use only if a second non-chemo therapeutic infusion is given on the same encounter. |
Common denial: billing 96413 (chemo IV) instead of 96365 for Nulojix. AMA CPT classifies
belatacept as a therapeutic (non-chemo) infusion. Use 96365 (+ 96366 if >1 hr) only. Persistent misuse
of 96413 attracts post-pay audit and chargeback.
Why not chemo admin: Chemotherapy administration codes apply to cytotoxic agents and a small
defined list of complex monoclonal antibodies for oncologic indications. Belatacept is a non-oncologic
immunomodulator (CTLA-4-Ig) approved for solid-organ transplant immunosuppression. AMA classifies its IV
administration as therapeutic IV (96365 series), not chemo (96413 series).
Modifiers CMS verified May 2026
JW — required on virtually every Nulojix claim
Because Nulojix is dosed by weight (10 mg/kg initial, 5 mg/kg maintenance) and supplied only in 250 mg single-dose vials, most calculated doses will not divide evenly into 250 mg increments. Partial-vial waste is the norm. CMS requires the JW modifier to report the discarded portion of a single-dose vial on a separate claim line.
JZ — required when no drug is discarded
Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. For Nulojix this is uncommon (it would require a calculated dose that lands exactly on a 250 mg multiple), but it can occur with specific weight bands. One of JZ or JW must appear on every J0485 claim.
Worked example — 70 kg recipient, 10 mg/kg initial-phase dose
# Calculated dose: 70 kg × 10 mg/kg = 700 mg
Vials needed: 700 / 250 = 2.8 → 3 vials drawn (750 mg)
Wasted drug: 750 − 700 = 50 mg discarded
# Billing
Line 1: J0485 700 units, modifier JZ (administered)
Line 2: J0485 50 units, modifier JW (waste)
# Total drug units reported: 750 (matches vials drawn)
Vials needed: 700 / 250 = 2.8 → 3 vials drawn (750 mg)
Wasted drug: 750 − 700 = 50 mg discarded
# Billing
Line 1: J0485 700 units, modifier JZ (administered)
Line 2: J0485 50 units, modifier JW (waste)
# Total drug units reported: 750 (matches vials drawn)
Common error: failing to bill the JW waste line. Wasted drug from a single-dose vial is
reimbursable but must be reported. Missing JW lines are a frequent audit finding. Bill the JW line with
the actual discarded units alongside the JZ-style administered units.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion (e.g., rejection workup, lab review, regimen change evaluation). Routine pre-infusion clinical assessment and vital signs are bundled.
340B modifiers (JG, TB)
For 340B-acquired Nulojix at participating transplant centers, follow your MAC's current 340B modifier
policy. Most MACs require JG on Part B claims for 340B drugs at hospital outpatient sites;
TB on rural / sole community hospital claims. Verify per MAC at billing time.
ICD-10-CM by indication FY2026 verified May 2026
Kidney transplant only. Use the most specific code supported by the chart for the transplant status / complication.
| Indication / context | ICD-10 | Notes |
|---|---|---|
| Kidney transplant status (post-op, no complication) | Z94.0 | Standard maintenance code for stable kidney transplant recipient on Nulojix |
| Kidney transplant rejection | T86.10 | Unspecified complication of kidney transplant; use when documenting rejection workup |
| Kidney transplant failure | T86.11 | Use for transplant failure complication coding |
| Kidney transplant infection | T86.13 | Document the specific infection separately (CMV, BK virus, etc.) |
| Other complication of kidney transplant | T86.19 | Use for non-rejection / non-failure / non-infection complications |
| Long-term (current) use of immunosuppressive therapy | Z79.899 | Maintenance reporting; use alongside primary T86.x / Z94.0 |
| Underlying ESRD pre-transplant context (history) | Z87.890 / N18.6 | Personal history of ESRD or current ESRD diagnosis where clinically relevant |
| EBV-seropositive carrier status (documentation) | Z22.8 | Document EBV-seropositive status to satisfy the boxed-warning + contraindication gate (NOT a separately billable line; supports PA) |
EBV documentation drives PA approval. Most major payers require the EBV IgG result attached
to the PA submission, not just an ICD-10 code. Submit the actual lab report (date, assay, result). Missing
EBV documentation is the leading Nulojix PA denial reason.
Off-label transplant types will be denied. Liver transplant (boxed warning — increased
mortality), heart, lung, and pancreas transplant are NOT approved indications and will not be covered.
Use only the kidney transplant family of codes.
Site of care & place of service Verified May 2026
Nulojix is administered at a transplant-experienced site. The FDA label and BMS Access Support program both emphasize that the drug be administered only by physicians experienced in immunosuppressive therapy and kidney transplant management. The transplant center HOPD is the dominant initial-phase site; freestanding infusion suites affiliated with the transplant center are acceptable for maintenance.
| Setting | POS | Claim form | Typical use |
|---|---|---|---|
| Transplant center HOPD (on-campus) | 22 | UB-04 / 837I | Primary site, initial phase — transplant team oversight |
| Transplant center HOPD (off-campus PBD) | 19 | UB-04 / 837I | Primary site, often for maintenance |
| Freestanding ambulatory infusion suite (transplant-affiliated) | 49 | CMS-1500 / 837P | Acceptable for stable maintenance after coordination with transplant team |
| Nephrology office | 11 | CMS-1500 / 837P | Less common; only with transplant-team co-management documented |
| Patient home | 12 | — | Not appropriate — transplant-team oversight (per boxed warning) precludes home administration |
Site-of-care UM: Some commercial payers will accept transition from transplant-center HOPD
to a freestanding infusion suite for stable maintenance Nulojix patients after the initial 12-week phase,
provided the transplant center remains the prescriber of record. Verify per payer policy and document the
co-management arrangement on the PA.
Claim form field mapping BMS Access Support 2026
From BMS Access Support — Nulojix HCP coding & coverage guidance.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider (transplant nephrologist / transplant surgeon) |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + 00003-0371-13 + ML + reconstituted volume (e.g., 30 mL for 3 vials drawn) |
| HCPCS J0485 + JZ (administered units) | 24D (drug line 1) | Bill actual mg administered as units (1 mg = 1 unit) |
| HCPCS J0485 + JW (waste units) | 24D (drug line 2) | Bill discarded mg as units on a separate line when partial-vial waste occurs |
| Drug units | 24G | 700 (administered, 70 kg initial) + 50 (waste) = 750 total reported for 3 vials drawn |
| CPT 96365 (admin line) | 24D (admin line) | Therapeutic IV, non-chemo. Add 96366 if >1 hr. |
| ICD-10 | 21 | Z94.0 (transplant status) primary; T86.1x for complications; Z79.899 for long-term immunosuppression |
| PA number | 23 | Required by all major payers; include EBV IgG result with PA |
Phase 3
Get paid
EBV serology documentation and the concomitant immunosuppression regimen are the make-or-break PA elements.
Payer policy snapshot Reviewed May 2026
All major payers require EBV-seropositive documentation and adult kidney-transplant indication. Off-label use will be denied.
| Payer | PA? | Required documentation | Other gates |
|---|---|---|---|
| UnitedHealthcare Medical Drug policy |
Yes | EBV IgG result (seropositive), adult kidney transplant, concomitant MMF + corticosteroid documentation | Transplant center prescriber preferred; site-of-care UM for maintenance |
| Aetna CPB on transplant immunosuppressants |
Yes | EBV-seropositive recipient, kidney transplant only, induction agent documented | Liver/heart/lung/pancreas transplant explicitly excluded; pediatric excluded |
| BCBS plans Plan-specific medical / pharmacy policies |
Yes | Generally aligned with KDIGO; EBV serology and concomitant regimen required | Plan-specific; many require transplant-center prescriber and re-PA annually |
| Medicare (Part B) MAC LCDs for transplant immunosuppressants |
No formal PA | FDA-labeled indication; documentation per MAC LCD | Coverage extends beyond 36 months post-transplant (Medicare transplant immunosuppressive drug benefit, B-only) |
| Medicaid (state-by-state) State formulary |
Usually | EBV serology, adult kidney transplant, concomitant regimen | Many state plans require step from CNI-based regimen with documented intolerance / contraindication |
Concomitant therapy expectations
- Induction: basiliximab (preferred per BENEFIT regimen) or institutional alternative. Document on PA.
- Mycophenolate mofetil (MMF): standard antimetabolite component. Document daily dose.
- Corticosteroids: per institutional taper protocol.
- Live vaccines: contraindicated during therapy. Document immunization status pre-transplant.
Step therapy & alternatives
Most commercial plans do NOT require step therapy from calcineurin-inhibitor (CNI) regimens for Nulojix approval in kidney transplant, but some Medicaid programs and selected commercial plans require documented CNI intolerance or contraindication (e.g., CNI-related nephrotoxicity, CNI-induced metabolic complications) for non-formulary Nulojix coverage. Document the rationale for CNI-sparing strategy.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J0485
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6%
$3.893
per 1 mg / per unit
Initial dose (700 mg / 70 kg)
$2,725.10
10 mg/kg administered, pre-JW waste
Maintenance (350 mg / 70 kg)
$1,362.55
5 mg/kg q4w, pre-JW waste
Annualized maintenance cost (Medicare ASP+6%, 70 kg patient, pre-sequestration):
Initial phase year 1 (6 initial doses @ 700 mg administered + waste) ~ $17,500 drug cost;
maintenance year (13 doses @ 350 mg administered) ~ $17,713 drug payment +
~$7,591 JW-billable waste. After ~2% sequestration, actual paid is roughly ASP + 4.3%.
Add facility infusion fee per 96365 RVU schedule.
Medicare Part B transplant immunosuppressive drug benefit
Belatacept is a covered immunosuppressive drug under the Medicare Part B transplant immunosuppressive drug benefit. Following the 2020 statutory change implemented in 2023, Medicare Part B coverage of immunosuppressive drugs for kidney transplant recipients is no longer time-limited to 36 months post-transplant for beneficiaries who would otherwise lose Medicare entitlement. Verify the specific beneficiary's Part B eligibility category before billing.
Coverage
No NCD specific to belatacept. Coverage falls under MAC LCDs for transplant immunosuppressants. All MACs cover J0485 for FDA-approved kidney transplant indications with appropriate documentation of EBV-seropositive status, indication, and concomitant regimen.
Code history
- J0485 — permanent code in continuous use since shortly after Nulojix's June 15, 2011 FDA approval. Descriptor: "Injection, belatacept, 1 mg."
- Pre-permanent-code period billed under unclassified
J3490with NDC documentation. - ASP refreshes quarterly — next update: July 1, 2026 for Q3 2026.
Patient assistance — BMS Access Support BMS verified May 2026
- BMS Access Support: 1-800-861-0048 — benefits investigation, prior authorization assistance, appeal support, alternate funding research
- Nulojix Co-Pay Assistance Program: commercially-insured patients may pay reduced cost per dose, subject to annual maximums; excludes Medicare, Medicaid, and other federal program patients (federal anti-kickback)
- BMS Patient Assistance Foundation: free product for uninsured / underinsured patients meeting income requirements (administered through the BMS Patient Assistance Program, Inc., a 501(c)(3))
- Foundations for Medicare patients: PAN Foundation, HealthWell Foundation, Good Days, Patient Advocate Foundation, NeedyMeds — verify open transplant / immunosuppression funds quarterly (funds open and close based on funding cycles)
- State kidney programs: some states maintain residual kidney drug assistance programs for transplant recipients; verify with the state Medicaid office
- Web: bmsaccesssupport.com · nulojix.com
Need to model what a specific transplant patient will actually pay after copay assistance, deductible,
coinsurance, and OOP max across the initial and maintenance phases?
Run a CareCost Estimate — J0485 pre-loaded with the weight-based picker.
Phase 4
Fix problems
Missing EBV serology is the #1 Nulojix denial. Wrong admin code (96413) and SC-vs-IV / abatacept-vs-belatacept confusion follow.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| #1 EBV serology not documented | PA submitted without EBV IgG result | Submit EBV IgG lab report (date, assay, result). Document EBV-seropositive status on the PA. EBV-seronegative or unknown is a hard contraindication — do not proceed without seropositive confirmation. |
| PTLD baseline risk assessment missing | No baseline PTLD risk assessment in chart | Document baseline lymphoma / lymphoproliferative history, EBV status, CMV status, and risk-factor assessment per the FDA boxed warning. |
| Prior PML risk factors not addressed | No documentation of JC virus / prior PML risk assessment | Document baseline neurologic exam and PML risk-factor screening per boxed warning. Re-screen on suspicion of CNS symptoms. |
| Concomitant immunosuppression not documented | PA missing MMF + corticosteroid regimen | Document induction agent (typically basiliximab), MMF dose, and corticosteroid taper on the PA. Most payers expect the BENEFIT regimen. |
| Initial vs maintenance phase confusion | Maintenance dose billed during initial phase or vice versa | Tie the dose to the post-transplant week. Initial phase: 10 mg/kg through end of week 12 (6 doses). Maintenance: 5 mg/kg from end of week 16 q4w. Re-bill at the correct phase. |
| Wrong admin code (96413) | Chemo IV billed instead of therapeutic IV | Resubmit with 96365 (+ 96366 if >1 hr). Belatacept is non-chemo per AMA classification. |
| Confused with abatacept (J0129) | Wrong HCPCS / wrong unit basis on the claim | Verify the active ingredient on the label. Belatacept = J0485 (1 mg = 1 unit, kidney transplant). Abatacept = J0129 (10 mg = 1 unit, autoimmune disease). Correct the HCPCS and re-bill. |
| JW missing on partial-vial waste | Discarded drug not reported | Add JW line for discarded units alongside the JZ-style administered line. Required for the weight-based dosing that nearly always produces partial-vial waste. |
| Off-label transplant type | Billed for liver / heart / lung / pancreas transplant | Not covered. Liver transplant carries a boxed warning for increased mortality. Other transplant types are not approved. Discontinue and switch to an approved regimen. |
| Pediatric use | Patient <18 years | Not covered — safety / efficacy not established. Switch to an age-appropriate regimen. |
| Wrong NDC format (vial-level) | Vial NDC submitted instead of carton NDC | Use carton NDC 00003-0371-13 with N4 qualifier and ML unit-of-measure. |
Frequently asked questions
What is the HCPCS code for Nulojix?
Nulojix (belatacept) is billed under HCPCS J0485 — "Injection, belatacept, 1 mg."
Each 1 mg equals one billable unit, so a 700 mg dose (10 mg/kg for a 70 kg recipient during the initial
phase) is 700 units. J0485 has been the permanent code since shortly after Nulojix's June 15, 2011 FDA
approval. The drug is supplied only as a 250 mg single-dose lyophilized vial for IV infusion.
Is Nulojix the same as Orencia (abatacept)?
No. Belatacept (Nulojix, J0485) and abatacept (Orencia, J0129)
are both CTLA-4-Ig fusion proteins from Bristol Myers Squibb, but they are distinct molecules with different
indications. Belatacept is approved only for prophylaxis of organ rejection in adult kidney transplant
recipients and has a higher binding avidity. Abatacept is approved for autoimmune disease (RA, JIA, PsA)
and acute GVHD prevention. They are not interchangeable; they have separate FDA labels, separate safety
profiles (Nulojix carries a boxed warning, Orencia does not), separate HCPCS codes, and separate dosing
regimens. Confusing the two is a common coding error.
Is EBV serology testing required before Nulojix?
Yes. Nulojix is contraindicated in transplant recipients who are Epstein-Barr Virus seronegative or whose EBV serostatus is unknown. EBV-seronegative recipients had approximately 13× higher risk of post-transplant lymphoproliferative disorder (PTLD), particularly CNS PTLD, in the registration trials. The boxed warning explicitly limits use to EBV-seropositive (EBV+) recipients. Document the EBV IgG result in the chart and on the PA submission. Missing EBV documentation is the #1 Nulojix denial cause.
What is the initial vs maintenance dosing schedule?
Initial phase: 10 mg/kg IV on Day 1 (day of transplant, prior to implantation), Day 5 (within 24 hours after transplant ±1 day), then at the end of weeks 2, 4, 8, and 12 post-transplant (6 initial-phase doses total). Maintenance phase: 5 mg/kg IV at the end of week 16 post-transplant, then every 4 weeks thereafter (±3 days) indefinitely. Round the calculated dose to the nearest 12.5 mg increment per the FDA label. Bill the initial-phase units separately from the maintenance-phase units; many payers verify phase against the post-transplant week.
Why is Nulojix approved only for kidney transplant — what about liver?
Nulojix carries a boxed warning against use in liver transplant recipients because a Phase II liver transplant study showed increased mortality and graft loss versus the comparator. Nulojix is therefore not approved and not recommended in liver transplant. It is also not recommended in solid-organ transplants other than kidney — the safety and efficacy in heart, lung, and pancreas transplant have not been established. Off-label use outside kidney transplant in EBV-seropositive adult recipients should be avoided and will not be covered by most payers.
What concomitant immunosuppression is required with Nulojix?
Nulojix is used as part of a multidrug immunosuppression regimen, not monotherapy. The BENEFIT and BENEFIT-EXT trials used Nulojix with basiliximab induction, mycophenolate mofetil (MMF), and a corticosteroid taper. KDIGO transplant guidelines align with this combination. Document the concomitant regimen (induction agent, antimetabolite, corticosteroid) in the chart and on the PA — most commercial payers expect MMF + corticosteroid as concomitant therapy, and absence of documentation triggers a denial for missing supporting regimen.
What is the boxed warning and what monitoring is required?
Nulojix carries a boxed warning for: (1) increased risk of post-transplant lymphoproliferative disorder (PTLD), predominantly involving the CNS — recipients must be EBV-seropositive; (2) increased risk of progressive multifocal leukoencephalopathy (PML) and other serious CNS infections; (3) increased risk of serious infections, including opportunistic infections; (4) use only by physicians experienced in immunosuppressive therapy and transplant management; (5) not recommended in liver transplant due to increased mortality. Monitor for neurologic symptoms, new or worsening adenopathy, and signs of opportunistic infection at every visit. CMV and PJP prophylaxis per institutional protocol.
Can Nulojix be used in pediatric kidney transplant recipients?
No. Nulojix safety and efficacy have not been established in pediatric patients (<18 years). The FDA label is limited to adult kidney transplant recipients. Pediatric off-label use is not recommended and will not be covered by major commercial payers or Medicaid. Pediatric kidney transplant immunosuppression typically uses calcineurin-inhibitor-based regimens; consult the transplant center for age-appropriate alternatives.
What is the Medicare reimbursement for J0485?
For Q2 2026, the Medicare Part B payment limit for J0485 is $3.893 per 1 mg unit (ASP + 6%). For a 70 kg recipient, the 700 mg initial-phase dose reimburses at approximately $2,725.10 per administration (administered drug; wasted drug billed separately under JW). The 350 mg maintenance dose reimburses at approximately $1,362.55. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%. ASP refreshes quarterly.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- Nulojix HCP — Bristol Myers Squibb product site
- Nulojix (belatacept) Prescribing Information — BMS package insert
- DailyMed — NULOJIX (belatacept) label
- BMS Access Support — Nulojix coding & coverage HCP page
- CMS — Medicare Part B Drug ASP Pricing File
- Vincenti F et al. Belatacept and Long-Term Outcomes in Kidney Transplantation (BENEFIT 7-yr) — NEJM 2016
- Vincenti F et al. A Phase III Study of Belatacept-based Immunosuppression in Renal Allograft Recipients (BENEFIT) — NEJM 2010
- KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
- UnitedHealthcare — Medical Drug Policy library
- Aetna — Clinical Policy Bulletin library
- FDA National Drug Code Directory
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, BCBS) | Semi-annual | Manual review against published payer policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label, boxed warning | Event-driven | Tied to BMS document version + FDA label revision date. |
Reviewer
Editorial audit complete — May 23, 2026. Page reconciled against the current DailyMed
Nulojix label (setid c16ac648-d5d2-9f7d-8637-e2328572754e, revision July 28, 2021), CMS Q2 2026 ASP file
(J0485 = $3.893 per mg), and the BMS package insert. Major correction: removed "REMS"
framing across the fact card, hero summary, Nulojix-vs-Orencia comparison, site-of-care table, FAQ, and
denials list — there is no current Nulojix REMS program. The EBV-seropositive requirement is enforced
by the boxed warning + contraindication, not REMS. Boxed-warning text rewritten to match the label's
single combined warning (PTLD / immunosuppression / not for liver transplant); PML and other CNS
infections moved to W&P framing (they are not separately boxed). Adult-only indication, dosing, and
HCPCS unchanged.
Change log
- — SME audit pass. Removed all references to a Nulojix REMS program (none exists per current label and DailyMed). Rewrote boxed-warning summary to match the label's single combined warning; corrected fact card, Nulojix-vs-Orencia comparison, FAQ, denials, and site-of-care text. Updated DailyMed link to setid c16ac648-d5d2-9f7d-8637-e2328572754e (rev July 28, 2021). Pricing, dosing, and HCPCS unchanged.
- — Initial publication. ASP data: Q2 2026 ($3.893 per 1 mg unit). Manufacturer source: BMS Access Support 2026. FDA label: most recent revision (BLA 125288). Indication: adult kidney transplant rejection prophylaxis in EBV-seropositive recipients only.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical / pharmacy policy documents. Indications and boxed warnings are verified against the current FDA label revision. We do not paraphrase from billing-software vendor blogs.